# Bridging Study With GSK239512 In Patients With Mild To Moderate Alzheimer's Disease

> **NCT00675090** · PHASE1 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 28 (actual)

## Conditions studied

- Alzheimer's Disease

## Interventions

- **DRUG:** GSK239512
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00675090
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-02-21
- **Primary completion:** 2009-06-16
- **Final completion:** 2009-06-16
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2017-07-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00675090

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00675090, "Bridging Study With GSK239512 In Patients With Mild To Moderate Alzheimer's Disease". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00675090. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*